Amphastar Pharmaceuticals (AMPH) Finished Goods (2015 - 2026)

Amphastar Pharmaceuticals has reported Finished Goods for 12 years, with the latest figure at $30.1 million in Q2 2026.

• On a quarterly basis, Finished Goods fell 27.62% year-over-year to $30.1 million in Q2 2026; TTM through Jun 2026 was $30.1 million, a 27.62% decrease from a year earlier, with the FY2025 full-year figure at $29.6 million, down 24.87% from the prior year.
• Finished Goods was $30.1 million for Q2 2026 at Amphastar Pharmaceuticals, up from $22.9 million in the prior quarter.
• The five-year high for Finished Goods was $41.6 million in Q2 2025, with the low at $14.5 million in Q1 2022.
• Average Finished Goods over 5 years is $27.9 million, with a median of $27.8 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Finished Goods surged 91.35% in 2023, then slumped 40.46% in 2026.
• Over 5 years, Finished Goods stood at $18.9 million in 2022, then surged by 31.99% to $24.9 million in 2023, then soared by 58.14% to $39.4 million in 2024, then dropped by 24.87% to $29.6 million in 2025, then grew by 1.65% to $30.1 million in 2026.
• The last three Finished Goods figures came in at $30.1 million (Q2 2026), $22.9 million (Q1 2026), and $29.6 million (Q4 2025), per Business Quant data.